News in English
Earlier this summer, a U.S. research group published a study showing that a larger proportion of patients than previously known discontinue their treatment with obesity medications prematurely. Nearly half of the patients in the study had stopped treatment early, which is a significantly higher rate than observed in the clinical trials that supported the approval of new obesity drugs such as Wegovy and Mounjaro.
Many discontinue obesity medication – new study highlights the reasons
A new study maps out the most common reasons why patients choose to stop taking obesity medication prematurely. “Obesity medication discontinuation reverses health benefits and prompts weight regain in most individuals,” says Hamlet Gasoyan, one of the researchers behind the new study, in an interview with Life Science Sweden.